ActiTrexx GmbH

Leading Innovators in GvHD Prevention 2022
Winners image
<p>The only curative approach for several blood cancers is the hematopoietic stem cell transplantation (HSCT). However, approx. 40% of patients receiving an allogeneic HSCT develop a severe transplant rejection, the graft-versus-host disease (GvHD) with massive organ inflammation, invalidity and lethality. ActiTrexx has developed a cellular drug (ATreg), which prevents GvHD. ATreg is a single infusion and will be manufactured and delivered within 24h upon ordering. </p>